On May 5, 2026 INmune Bio Inc. (NASDAQ: INMB) ("INmune Bio"), a clinical-stage biotechnology company, and Anthony Nolan, a pioneering UK-based charity that set up the world’s first stem cell register and is now driving forward cell therapy advancements, reported the signing of an amended and restated Material Transfer and License Agreement. This expanded collaboration secures the long-term provision of high-quality umbilical cord tissue to power INmune Bio’s CORDStrom platform, the industry’s most advanced Mesenchymal Stromal Cell (MSC) technology designed to deliver consistent, scalable, and "off-the-shelf" cellular therapies which are suitable for supply in UK, EU and US, as well as other global regions.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The restated agreement, effective April 29, 2026, solidifies the partnership between Anthony Nolan’s Cell Therapy and Laboratory Services, which draws on 50 years of pioneering innovation, research and expertise, and INmune Bio’s international and domestic entities to support the development of human medicinal products subject to global regulatory oversight, including the FDA, EMA, and MHRA.
Solving the MSC Consistency Challenge
While MSCs have long shown therapeutic promise, the industry has struggled with donor variability and manufacturing inconsistency. CORDStrom addresses these hurdles by utilizing umbilical cord-derived MSCs which are tested, screened and pooled to create standardized "MSC Banks". By leveraging Anthony Nolan’s Cell Therapy & Laboratory Services’ world-class procurement and screening infrastructure, INmune Bio ensures that every CORDStrom product meets rigorous "Materials Acceptance Criteria," including precise neonatal weight and maternal age specifications, to ensure the highest reproducibility whilst ensuring regulatory compliance.
A Robust Pipeline: From RDEB to Oncology
The collaboration is initially focused on several high-impact "Initial Indications" and next-generation therapeutic candidates:
● Recessive Dystrophic Epidermolysis Bullosa (RDEB): Development of CORDStrom as a transformative treatment for this devastating skin-fragility disorder.
● CORDStrom-col7a: A next-generation systemic treatment for EB designed to address the underlying genetic deficiencies of the disease.
● CORDStrom-TRAIL (Oncology): Targeted expansion into solid tumors, utilizing the platform’s immunomodulatory capabilities to combat cancer.
● Inflammatory & Degenerative Diseases: The platform will also be deployed to address the massive unmet needs in Osteoarthritis and Systemic Lupus Erythematosus (SLE).
Management Commentary
"We view CORDStrom as a tremendous platform that finally solves the fundamental challenge of understanding MSCs as a drug," said David Moss, CEO of INmune Bio. "By partnering with Anthony Nolan’s Cell Therapy & Laboratory Services, we are combining the most advanced MSC cell platform with the most reliable source of cellular starting material. This collaboration allows us to move beyond the limitations of traditional cell therapy and provide consistent, high-potency treatments for patients suffering from RDEB, cancer, and chronic inflammatory conditions. We remain hugely grateful to the volunteer donors who provide the UC for our program and who consent to UK and US testing to make CORDStrom universally available".
"Anthony Nolan is committed to supporting the development of innovative cell and gene therapies to help more patients survive and thrive," said Nicola Alderson, COO of Anthony Nolan. "This partnership with our Cell Therapy and Laboratory Services allows our donor materials to reach their full potential within a cutting-edge manufacturing platform, facilitating the development of medicinal products that meet the highest ethical and regulatory standards for patients worldwide".
Agreement Terms
The agreement includes rigorous provisions for traceability and quality management, ensuring that all materials are handled in accordance with Good Manufacturing Practice (GMP) and Human Tissue Authority (HTA) standards as INmune Bio prepares for commercial approval of CORDStrom.
(Press release, INmune Bio, MAY 5, 2026, View Source [SID1234665119])